ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.Bandarage, U.K., Cao, J., Come, J.H., Court, J.J., Gao, H., Jacobs, M.D., Marhefka, C., Nanthakumar, S., Green, J.
(2018) Bioorg Med Chem Lett 28: 2622-2626
- PubMed: 30082069
- DOI: https://doi.org/10.1016/j.bmcl.2018.06.040
- Primary Citation of Related Structures:
- PubMed Abstract:
Rho kinase (ROCK) inhibitors are potential therapeutic agents for the treatment of a variety of disorders including hypertension, glaucoma and erectile dysfunction. Here we disclose a series of potent and selective ROCK inhibitors based on a substituted 7-azaindole scaffold. Substitution of the 3-position of 7-azaindole led to compounds such as 37, which possess excellent ROCK inhibitory potency and high selectivity against the closely related kinase PKA.
Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, USA.